Prothena Corp Public Ltd Co (PRTA) stock
PRTANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3017% below fair value
$8.16−0.07 (-0.85%)
Close on Nov 13, 2026Market cap $418.91MP/E –Yield –
Prothena Corp Public r&d expenses
Research and development expenses are spending on new products and technology.
Prothena Corp Public's R&D Expenses for the twelve months ending Sep 30, 2026 was $44.44M, down 73.9% year over year. For fiscal 2025 it was $134.85M, down 39.4% from the year before. Over ten years it grew 8.7% a year on average. The highest annual figure on record is $222.52M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $134.85M | -39.4% |
| FY2024 | Dec 31, 2024 | $222.52M | +0.9% |
| FY2023 | Dec 31, 2023 | $220.57M | +62.7% |
| FY2022 | Dec 31, 2022 | $135.56M | +64.7% |
| FY2021 | Dec 31, 2021 | $82.28M | +9.9% |
| FY2020 | Dec 31, 2020 | $74.88M | +47.3% |
| FY2019 | Dec 31, 2019 | $50.84M | -49.8% |
| FY2018 | Dec 31, 2018 | $101.18M | -24.8% |
| FY2017 | Dec 31, 2017 | $134.55M | +12.6% |
| FY2016 | Dec 31, 2016 | $119.53M | +104.5% |
| FY2015 | Dec 31, 2015 | $58.44M | +52.0% |
| FY2014 | Dec 31, 2014 | $38.45M | +47.6% |
| FY2013 | Dec 31, 2013 | $26.05M | -23.7% |
| FY2012 | Dec 31, 2012 | $34.14M | +41.2% |
| FY2011 | Dec 31, 2011 | $24.17M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $8.43M | -70.9% |
| Q2 FY2026 | Jun 30, 2026 | $8.80M | -78.3% |
| Q1 FY2026 | Mar 31, 2026 | $12.63M | -75.1% |
| Q4 FY2025 | Dec 31, 2025 | $14.59M | -70.9% |
| Q3 FY2025 | Sep 30, 2025 | $28.94M | -42.9% |
| Q2 FY2025 | Jun 30, 2025 | $40.52M | -29.5% |
| Q1 FY2025 | Mar 31, 2025 | $50.81M | -20.7% |
| Q4 FY2024 | Dec 31, 2024 | $50.17M | -18.9% |
| Q3 FY2024 | Sep 30, 2024 | $50.72M | -12.4% |
| Q2 FY2024 | Jun 30, 2024 | $57.51M | +2.7% |
| Q1 FY2024 | Mar 31, 2024 | $64.11M | +43.3% |
| Q4 FY2023 | Dec 31, 2023 | $61.89M | +67.9% |
| Q3 FY2023 | Sep 30, 2023 | $57.91M | +45.3% |
| Q2 FY2023 | Jun 30, 2023 | $56.01M | +77.4% |
| Q1 FY2023 | Mar 31, 2023 | $44.76M | +64.2% |
| Q4 FY2022 | Dec 31, 2022 | $36.87M | +67.2% |
| Q3 FY2022 | Sep 30, 2022 | $39.86M | +121.5% |
| Q2 FY2022 | Jun 30, 2022 | $31.57M | +49.7% |
| Q1 FY2022 | Mar 31, 2022 | $27.26M | +28.9% |
| Q4 FY2021 | Dec 31, 2021 | $22.06M | +6.3% |
| Q3 FY2021 | Sep 30, 2021 | $17.99M | -16.7% |
| Q2 FY2021 | Jun 30, 2021 | $21.09M | +22.1% |
| Q1 FY2021 | Mar 31, 2021 | $21.14M | +38.7% |
| Q4 FY2020 | Dec 31, 2020 | $20.76M | +34.2% |
| Q3 FY2020 | Sep 30, 2020 | $21.61M | +73.0% |
| Q2 FY2020 | Jun 30, 2020 | $17.27M | +80.2% |
| Q1 FY2020 | Mar 31, 2020 | $15.25M | +14.7% |
| Q4 FY2019 | Dec 31, 2019 | $15.47M | -6.3% |
| Q3 FY2019 | Sep 30, 2019 | $12.49M | -32.6% |
| Q2 FY2019 | Jun 30, 2019 | $9.58M | -69.5% |
| Q1 FY2019 | Mar 31, 2019 | $13.30M | -61.7% |
| Q4 FY2018 | Dec 31, 2018 | $16.51M | -50.7% |
| Q3 FY2018 | Sep 30, 2018 | $18.52M | -55.2% |
| Q2 FY2018 | Jun 30, 2018 | $31.45M | -7.6% |
| Q1 FY2018 | Mar 31, 2018 | $34.71M | +35.1% |
| Q4 FY2017 | Dec 31, 2017 | $33.50M | -15.9% |
| Q3 FY2017 | Sep 30, 2017 | $41.32M | – |
| Q2 FY2017 | Jun 30, 2017 | $34.03M | – |
| Q1 FY2017 | Mar 31, 2017 | $25.70M | – |
| Q4 FY2016 | Dec 31, 2016 | $39.84M | – |
See a number that looks wrong?